Home » Newsletters » BioWorld Science

BioWorld Science

April 11, 2019

View Archived Issues

Diversion is novel way of enzyme inhibition

Potassium promotes T-cell stemness

New model to trial schizophrenia preventative treatments

FDA accepts IND application for first-in-human study of PSB-205

Galapagos initiates first-in-human trial of GLPG-3121

U.S. researchers present a 5-HT2A receptor inhibitor antibody

Merck & Co. identifies new nicotinic alpha-7 receptor positive allosteric modulators

CCDC102B is strongly correlated with negative clinical outcome in breast cancer

Menin/MLL interaction inhibitors discovered at Kura Oncology

Kymera Therapeutics discovers protein cereblon inhibitors

ESSA Pharmaceuticals presents the characterization of next-generation Anitens

Leo Pharma patents phosphodiesterase PDE4D inhibitors

ABM Therapeutics presents V600E mutant raf kinase B inhibitors

Phase Ib/II data presented for DV-281 in combination with nivolumab in patients with NSCLC

New and potent IDO1 inhibitors from Merck & Co. presented

I-Mab Biopharma collaborates with Roche on clinical study of TJD-5 with Tecentriq

Alkeus begins phase III study of ALK-001 for GA secondary to AMD

Sanaria announces agreements to support development of PfSPZ vaccine for malaria

AstraZeneca DNA-PK inhibitor AZD-7648 has single-agent and combination antitumor activity

New phase I trial evaluates AVID-200 in patients with myelofibrosis

Evotec and Indivumed to use IndivuType database for colorectal cancer drug discovery

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 3, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...
5-HT2R allosteric ligands attenuate cocaine use and seeking behavior
BioWorld Science
Serotonergic G-protein-coupled receptors (GPCRs), including the 5-HT2A receptor (5-HT2AR) and 5-HT2CR, are key regulators of cortical signaling pathways and...